Pre-release: this release has not been published. Identifiers are permanent; descriptions may still change.
21 U.S.C. 360bbb Expanded access to unapproved therapies and diagnostics
21 U.S.C. 360bbb Expanded access to unapproved therapies and diagnostics, “Expanded access to unapproved therapies and diagnostics”, is a U.S. Code section of Part E—General Provisions Relating to Drugs and Devices; in force.
https://ontology.bommaritollc.com/id/01a0f06c-cd38-7075-88aa-4ae03ffd903d
Elsewhere
Facts
| adms:identifier | |
| eli:cites | |
| prov:wasDerivedFrom | |
| schema:isPartOf | |
| schema:legislationIdentifier | 21 U.S.C. 360bbb |
| schema:legislationJurisdiction | |
| schema:legislationLegalForce | |
| schema:legislationType | |
| schema:name | Expanded access to unapproved therapies and diagnosticsen |
| schema:url | |
| skos:prefLabel | 21 U.S.C. 360bbb Expanded access to unapproved therapies and diagnosticsen |
Related
Cited by (15)eli:cites
- 10 U.S.C. 1110 System for tracking and recording vaccine information; anthrax vaccine immunization program
- 21 U.S.C. 355 New drugs
- 21 U.S.C. 355-1 Risk evaluation and mitigation strategies
- 21 U.S.C. 360bbb-0 Expanded access policy required for investigational drugs
- 21 U.S.C. 360bbb-0a Investigational drugs for use by eligible patients
- 21 U.S.C. 360j General provisions respecting control of devices intended for human use
- 21 U.S.C. 379k-1 Electronic format for submissions
- 42 CFR 11.10 What definitions apply to this part?
- 42 CFR 11.64 When must clinical trial information submitted to ClinicalTrials.gov be updated or corrected?
- 42 U.S.C. 247d-6b Strategic National Stockpile and security countermeasure procurements
- 42 U.S.C. 247d-6d Targeted liability protections for pandemic and epidemic products and security countermeasures
- 42 U.S.C. 247d-7e Biomedical Advanced Research and Development Authority
- 42 U.S.C. 280g-7b HHS public-private partnership for rare neurodegenerative diseases
- 42 U.S.C. 282 Director of National Institutes of Health
- 42 U.S.C. 300hh-10 Coordination of preparedness for and response to all-hazards public health emergencies
Rules made under it (2)eli:based_on
- 21 CFR Part 312—Investigational new drug application
- 21 CFR Part 4—Regulation of combination products